HomeCompareHTBX vs BTI

HTBX vs BTI: Dividend Comparison 2026

HTBX yields 84.03% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HTBX wins by $1.95M in total portfolio value
10 years
HTBX
HTBX
● Live price
84.03%
Share price
$2.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.98M
Annual income
$593,470.68
Full HTBX calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — HTBX vs BTI

📍 HTBX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHTBXBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HTBX + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HTBX pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HTBX
Annual income on $10K today (after 15% tax)
$7,142.86/yr
After 10yr DRIP, annual income (after tax)
$504,450.08/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, HTBX beats the other by $502,081.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HTBX + BTI for your $10,000?

HTBX: 50%BTI: 50%
100% BTI50/50100% HTBX
Portfolio after 10yr
$1.01M
Annual income
$298,128.66/yr
Blended yield
29.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

HTBX
Analyst Ratings
8
Buy
Consensus: Buy
Altman Z
-22.5
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HTBX buys
0
BTI buys
0
No recent congressional trades found for HTBX or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHTBXBTI
Forward yield84.03%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$1.98M$37.7K
Annual income after 10y$593,470.68$2,786.64
Total dividends collected$1.73M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: HTBX vs BTI ($10,000, DRIP)

YearHTBX PortfolioHTBX Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$19,103$8,403.36$11,299$598.92+$7.8KHTBX
2$35,444$15,003.03$12,794$703.91+$22.6KHTBX
3$63,940$26,014.99$14,518$829.07+$49.4KHTBX
4$112,276$43,860.35$16,513$978.64+$95.8KHTBX
5$192,114$71,978.72$18,827$1,157.84+$173.3KHTBX
6$320,666$115,104.62$21,518$1,373.12+$299.1KHTBX
7$522,671$179,557.63$24,657$1,632.46+$498.0KHTBX
8$832,781$273,523.56$28,329$1,945.74+$804.5KHTBX
9$1,298,375$407,299.36$32,637$2,325.33+$1.27MHTBX
10$1,982,732$593,470.68$37,708$2,786.64+$1.95MHTBX

HTBX vs BTI: Complete Analysis 2026

HTBXStock

Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

Full HTBX Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this HTBX vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HTBX vs SCHDHTBX vs JEPIHTBX vs OHTBX vs KOHTBX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.